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Abstract
Background: Gaucher disease (GD) presents with a range of signs and symptoms. Phy-
sicians can fail to recognise the early stages of GD owing to a lack of disease awareness,
which can lead to significant diagnostic delays and sometimes irreversible but avoidable
morbidities.
Aim: The Gaucher Earlier Diagnosis Consensus (GED-C) initiative aimed to identify
signs and co-variables considered most indicative of early type 1 and type 3 GD, to help
non-specialists identify ‘at-risk’ patients who may benefit from diagnostic testing.
Methods: An anonymous, three-round Delphi consensus process was deployed among
a global panel of 22 specialists in GD (median experience 17.5 years, collectively man-
aging almost 3000 patients). The rounds entailed data gathering, then importance rank-
ing and establishment of consensus, using 5-point Likert scales and scoring thresholds
defined a priori.
Results: For type 1 disease, seven major signs (splenomegaly, thrombocytopenia,
bone-related manifestations, anaemia, hyperferritinaemia, hepatomegaly and
gammopathy) and two major co-variables (family history of GD and Ashkenazi-Jewish
ancestry) were identified. For type 3 disease, nine major signs (splenomegaly, oculomo-
tor disturbances, thrombocytopenia, epilepsy, anaemia, hepatomegaly, bone pain,
motor disturbances and kyphosis) and one major co-variable (family history of GD)
were identified. Lack of disease awareness, overlooking mild early signs and failure to
consider GD as a diagnostic differential were considered major barriers to early
diagnosis.
Conclusion: The signs and co-variables identified in the GED-C initiative as potentially
indicative of early GD will help to guide non-specialists and raise their index of suspi-
cion in identifying patients potentially suitable for diagnostic testing for GD.
Introduction
Gaucher disease (GD) is an autosomal recessive, genetic
disease that reduces levels of the enzyme
glucocerebrosidase in the lysosome. Glucocerebrosidase is
a key enzyme in the catabolism of the sphingolipid
glucosylceramide, and deficiency of this enzyme results in
accumulation of glucosylceramide in macrophages, which
then accumulate in the bone marrow, liver, lungs, spleen
and brain.1 At least 200 pathogenic variants of the
glucocerebrosidase gene have been identified.2 Patients
with GD may present with a broad range of signs and
symptoms, and a continuum of disease severity is
observed. The three disease phenotypes (GD types 1–3)
are also diverse,3 ranging from cases that are lethal within
a few months from birth,4 to mild or asymptomatic forms
in which symptoms may not appear until as late as the
eighth decade of life.3,5 Most patients present with the
non-neuronopathic type 1 form (with a prevalence of 1 in
40 000–60 000 in the general population rising to approxi-
mately 1 in 850 among individuals with Ashkenazi Jewish
ancestry),6–8 and may experience clinical problems, includ-
ing bone pain, bone fracture, osteoporosis, anaemia,
thrombocytopenia, reduced growth, thrombocytopenia,
bleeding, anaemia and hepatosplenomegaly. Neurological
complications are rarely seen in type 1 disease but are
more common in types 2–3.
Given its rarity and heterogeneous nature, identifying
patients for GD diagnostic testing remains a challenge in
clinical practice (see case study in Fig. 1),9 and it is common
for patients to experience substantial delays between symp-
tom onset and diagnosis. In a UK-based retrospective
review (n = 86), the median time from first symptoms to
diagnosis was 2 years (range: 0.5–26.0 years) and was
5.0 years or longer for almost one-fifth of patients.10 Possi-
ble reasons for exclusion of GD from differential diagnoses
may be poor disease awareness among clinicians or
because investigation of other diagnostic possibilities associ-
ated with greater mortality takes precedence.9–11 Differen-
tial diagnoses may also be impeded by multiple referrals
among medical specialists before a correct diagnosis is
reached. Patients may visit up to eight (mean: 3.0) different
specialists, including internists, paediatricians,
haematologists, medical oncologists, gastroenterologists,
geneticists, neurologists, obstetricians/gynaecologists,
orthopaedists and rheumatologists.11
Diagnostic delays may lead to irreversible or prevent-
able GD complications such as avascular necrosis,
chronic bone pain, pathologic fractures, growth failure,
life-threatening sepsis, liver abnormalities and severe
bleeding.11 In addition, patients often undergo unneces-
sary, invasive investigations (e.g. liver and bone marrow
biopsies or splenectomy) before GD is diagnosed.11 The
Early diagnosis of GD: expert consensus
Internal Medicine Journal 49 (2019) 578–591
© 2018 The Authors. Internal Medicine Journal by Wiley Publishing Asia Pty Ltd on behalf of Royal Australasian College of Physicians.
579
Figure 1 Type 1 Gaucher disease case study.
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potential for such delays to impact on patient morbidity
and quality of life is supported by the emergence of evi-
dence on the benefits of early diagnosis.12 A GD diagno-
sis is confirmed with enzymatic and/or blood-based
genetic tests,1 but awareness among non-specialists of
available diagnostic services and regional differences in
availability and in cost generally exclude GD testing from
routine bloodwork. Algorithms have been developed to
promote timely diagnosis of GD but they are typically
aimed at specialists.13,14 There is no consensus or guide-
line for identifying patients who may have early-stage
GD that is suited to non-GD specialists.
The Gaucher Earlier Diagnosis Consensus (GED-C)
initiative is an ongoing global project that has applied
Delphi methodology15–17 to build expert consensus on
aspects relating to diagnosis and management of
GD. Here, we summarise findings from the GED-C initia-
tive regarding consensus on signs and patient co-
variables suggestive of early type 1 or type 3 GD, on the
most important barriers to early GD diagnosis, and on
the likely impact of the initiative on patients and clini-
cians. We also propose some guidance for non-specialists
to help them both identify patients who may have GD
and confirm or discount GD in the differential diagnosis.
Methods
The iterative Delphi process is summarised in Figure 2.
Consensus is often reached within three rounds.15–17
Selection of Chairs and expert panel
Three co-Chairs were appointed: two clinical co-Chairs
recognised globally as leading GD experts, and one non-
clinical Chair with expertise in Delphi techniques who
provided critical methodological input. The clinical co-
Chairs nominated individuals with established GD exper-
tise (e.g. relevant research activities, participation in GD
management initiatives or authorship of peer-reviewed
publications) to form the voting panel. Nominated indi-
viduals were recruited by an independent third-party
administrator (Oxford PharmaGenesis Ltd, Oxford, UK)
and asked to respond independently to questions and
remained anonymous to each other throughout the pro-
cess. Based on published estimates that Delphi studies
typically enrol 15–20 participants,17 it was agreed a priori
that a panel of 22 experts was needed to provide ade-
quate study power in case of dropouts.
Delphi process
All stages were overseen by the Chairs and conducted by
the independent administrator. The administrator
gathered the panel members’ responses using an online
survey platform (SurveyMonkey, SurveyMonkey
Europe, Dublin, Ireland) and blinded data before sharing
with the co-Chairs. In round 1 (Supporting Information
Appendix S1), the expert panel provided free-text
answers to open questions about: clinical signs and co-
variables considered indicative of early type 1 or type
3 GD; barriers to diagnosis of GD; and the potential
impact of the GED-C initiative.
‘Early’ disease was defined as the time before symp-
toms impacted significantly on the quality of life. The
administrator grouped responses from round 1 into simi-
lar themes, which the co-Chairs checked, revised and
consolidated into factors (for clinical signs and co-vari-
ables) or statements (for ‘barriers to early GD diagnosis’
and ‘impact of the GED-C initiative’). In round 2 (Appen-
dix S2), the panel rated the importance of each factor or
statement using a 5-point Likert scale (1, not important;
2, slightly important; 3, important; 4, very important;
5, extremely important). Factors or statements awarded
an importance score of 3 or more by more than 75% of
respondents were taken to round 3. Factors not reaching
this threshold were classified as ‘minor’; statements not
reaching this threshold were excluded. In round
3 (Appendix S3), panel members indicated their level of
agreement with each factor or statement using a 5-point
pivoted Likert scale (1, strongly disagree; 2, disagree;
3, neither agree nor disagree; 4, agree; 5, strongly agree).
Consensus was defined a priori as more than 67% of the
panel awarding an agreement score of 4 or more. Factors
meeting these criteria were classified as major, otherwise
as minor. Statements not meeting these criteria were
excluded.
Statistical analyses
All data are reported descriptively owing to the explor-
atory (non-hypothesis testing) nature of the study.
Literature review of presenting signs in GD at
diagnosis
In parallel with the Delphi consensus, a comprehen-
sive literature search was performed to compile
evidence for the most common presenting signs at GD
diagnosis. A detailed methodology is provided in
Appendix S4.
Ethical approval
No patient data were required for conduct of this study,
so no ethical approval was sought.
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Results
Demographic and clinical practice
information for the GED-C expert panel
The expert panel comprised 22 practising physicians,
representing 16 different countries (Argentina, Australia,
Brazil, France, Germany, India, Ireland, Israel, Italy,
Japan, The Netherlands, Russia, Spain, Sweden, UK and
USA). All members had experience of managing type
1 GD, 19 also having managed type 3 GD. None had
managed only type 3 GD, and experience of type 2 GD
was not recorded. Collectively, the panel had more than
400 years of GD management experience (median,
17.5 years (range 6–40 years)) and had treated nearly
3000 patients with GD. Medical specialities of the expert
panel represented those of physicians who would typi-
cally encounter patients with GD or who would confirm
a diagnosis, including haematologists, paediatricians and
experts in inborn errors of metabolism (Fig. 3). The
panel members practised in public teaching/non-
teaching hospitals (n = 17), or in private hospitals/
clinics/research centres (n = 5). For all questions, a
response rate of 100% was achieved at each round of
the consensus.
Presenting signs and patient co-variables
in early type 1 GD
For presenting signs in early type 1 GD, 84 individual
free-text phrases were supplied in round 1 and grouped
into 29 themes. Seven themes (i.e. dental problems,
depression, elevated β2-microglobulin levels, elevated
chitotriosidase levels, generalised pain, liver cirrhosis
including abnormal liver function tests, and lymphade-
nopathy) were discarded as being either of low diagnos-
tic value in GD or unlikely to be available in a patient’s
Figure 2 The Gaucher Earlier Diagnosis Consensus initiative Delphi methodology.
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history. A further four themes were merged with others
to yield 18 consolidated themes (termed ‘factors’) for
assessment in round 2 (Appendix S5). Eight factors met
the importance criteria in round 2 and were taken for-
ward to round 3, in which consensus was reached on
seven; these factors were classified as major signs. Of the
remaining 11 factors from rounds 2 and 3, nine were
classified as minor signs, and two were discounted as
being of low relevance in early type 1 GD (Table 1).
Similarly, for patient co-variables in early type 1 GD,
20 individual free-text phrases were provided and
grouped into nine themes. Two themes were discarded
owing to their rarity (blood relative who died of foetal
hydrops and/or with diagnosis of neonatal sepsis of
uncertain aetiology; and child of consanguineous par-
ents), and two were discarded for being of low diagnostic
power in type 1 GD (age ≤18 years; age >18 years).
Consolidation of the themes, including merging two
themes with others, left three factors for consideration in
round 2 (Appendix S6). Two factors met the importance
criteria and were taken forward to round 3, and both
met the consensus criteria. These two factors were classi-
fied as major co-variables and the remaining factor as a
minor co-variable (Table 1).
Presenting signs and patient co-variables in
early type 3 GD
The panel provided 55 individual free-text phrases relat-
ing to early type 3 GD signs, and these were grouped
into 24 themes. Six themes were discarded as being of
low diagnostic power (dysphagia, elevated serum acid
phosphatase levels, gallstones, lymphadenopathy, par-
aesthesia and recurrent viral illness), leaving 18 factors
for consideration in round 2 (Appendix S7). Of 13 factors
that met the importance criteria in round 2, nine met
the consensus criteria in round 3. These were classified
as major signs, and the remaining nine factors from
rounds 2 and 3 were classified as minor signs (Table 2).
There were 15 individual free-text phrases relating to co-
variables in type 3 GD, and these were grouped into
10 themes. Four themes were discounted owing to their
rarity (Japanese or Taiwanese ancestry, Norbottnian Swed-
ish ancestry, Palestinian Arabic ancestry and the L444P
allele in Ashkenazi Jewish patients), and one theme was
discounted as being of low clinical relevance (age >18 years).
Of the five remaining factors assessed in round 2 (Appendix
S8), three met the importance criteria, and consensus was
reached for one of these in round 3. This was classified as a
major co-variable, and the other four factors from rounds
2 and 3 were classified as minor co-variables (Table 2).
Levels of major signs considered consistent
with a diagnosis of GD
During round 3, for major signs that were continuous rather
than categorical variables (anaemia, hyperferritinaemia,
hepatomegaly, splenomegaly and thrombocytopenia), most
of the panel members believed that mild or moderate levels
were consistent with early type 1 GD or early type 3 GD.
However, except for splenomegaly, the panel tended to be
divided about whether severe levels of each sign were con-
sistent with early type 1 GD or type 3 GD (Fig. 4).
Consensus on the barriers to early GD
diagnosis and the impact that the GED-C
initiative could have on clinical practice
Regarding barriers to early GD diagnosis, 47 individual
phrases were provided in round 1, grouped into nine
Figure 3 Characteristics of the experts involved in the Gaucher Earlier
Diagnosis Consensus initiative (n = 22). (A) Years of experience in man-
aging patients with Gaucher disease; (B) number of patients the expert
has treated; (C) clinical specialty.
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themes and consolidated into nine statements. In round
2, six statements met the importance criteria, and all met
the consensus criteria in round 3. The highest-scoring
diagnostic-barrier statement (mean score of 4.41 in
round 3) was ‘Owing to its rarity, there is a lack of aware-
ness of GD among healthcare professionals’ (Table 3).
In response to questions about the potential impact of
the initiative, 30 individual phrases were submitted and
grouped into eight themes. These were consolidated into
eight statements, all of which met the importance criteria
in round 2. Consensus was reached for seven of the state-
ments. The highest-scoring impact statements (mean
scores of 4.55 in round 3) were that ‘Patients could be
diagnosed earlier in the disease course and monitored
and managed appropriately to improve long-term out-
comes and quality of life’ and that ‘Earlier diagnosis
would help to reduce serious or irreversible late-onset
complications, and comorbidities of the disease could be
avoided or managed appropriately’ (Table 3).
Discussion
This international, multidisciplinary GED-C initiative has
identified a series of major and minor clinical signs and
co-variables that may facilitate the early diagnosis of GD
among non-specialist physicians and has provided impor-
tant expert insights into the greatest barriers to early GD
diagnosis. Collectively for type 1 and 3 GD, the GED-C
initiative identified 11 different major signs and two co-
variables indicative of early GD (Table 4). Based on these
findings the authors suggest that the unexplained pres-
ence of at least two signs, or of one unexplained sign in
conjunction with one of the co-variables should cause
physicians to consider GD in their differential diagnosis.
Table 1 Presenting clinical signs and co-variables in early type 1 GD
Round 2 Round 3














Major Splenomegaly 4.77 5 100 4.86 5 100
Thrombocytopenia 4.45 5 95 4.68 5 91
Bone issues including pain, crises, AVN and
fractures
4.00 4 91 4.45 5 91
Anaemia 3.77 4 95 4.05 4 86
Hepatomegaly 3.68 3.5 95 3.95 4 77
Elevated ferritin levels 3.50 4 82 4.05 4 86
Gammopathy – monoclonal or polyclonal 3.23 3 82 3.64 4 73
Minor Bleeding, bruising or coagulopathy 3.59 4 86 3.68 4 64
Elevated serum angiotensin-converting enzyme
levels
3.18 3.5 64 — — —
Growth retardation including low body weight 3.00 3 73 — — —
Low bone mineral density 2.95 3 59 — — —
Fatigue 2.82 3 64 — — —
Asthenia 2.59 2.5 50 — — —
Leukopenia 2.50 3 55 — — —
Gallstones 2.32 2 45 — — —
Dyslipidaemia 2.27 2 36 — — —
Discounted Neonatal cholestasis 1.73 2 9 — — —
Elevated bilirubin levels 1.68 1.5 14 — — —
Co-variables
Major Family history of GD 4.27 4.5 95 4.45 5 91
Jewish ancestry 3.91 4 86 4.18 4 86
Minor Family history of PD 3.14 3 73 — — —
Signs and co-variables that did not meet the threshold for importance (a score of ≥3 by >75% of respondents) were classified as minor and not taken
forward to round 3 for agreement rating. Signs and co-variables that met the threshold for agreement in round 3 (a score of ≥4 by >67% of respon-
dents) were classified as major; any that did not meet this threshold were classified as minor. Certain low-scoring signs were discounted as being of lit-
tle relevance in early type 1 GD. †The Likert scale used for importance rating in round 2 was: 1 = not important; 2 = slightly important; 3 = important;
4 = very important; 5 = extremely important. ‡The Likert scale used for agreement rating in round 3 was: 1 = strongly disagree; 2 = disagree; 3 = nei-
ther agree nor disagree; 4 = agree; 5 = strongly agree. §Percentage of respondents (n = 22) is the proportion awarding a Likert scale score that met
the selection criteria in each round. AVN, avascular necrosis; GD, Gaucher disease; PD, Parkinson disease.
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The importance of considering GD increases with the
number of unexplained signs and co-variables, and investi-
gation of the possibility of GD may require specialist refer-
ral. A specialist suspecting GD will test for low levels
(typically 10–15% of normal) of lysosomal
glucocerebrosidase, either in dried blot spots, which are rel-
atively quick to prepare and submit for laboratory testing,
or in total leukocytes, mononuclear cells or cultured fibro-
blasts, which provide a more reliable indication of defi-
ciency.1 Diagnosis of GD is confirmed by DNA sequencing
of the glucocerebrosidase gene. In the event of a positive
diagnosis, specialist involvement is highly recommended to
ensure that appropriate patient assessment and manage-
ment plans are instigated as soon as possible.
Treatment of GD involves intravenous infusion of the
deficient glucocerebrosidase enzyme every 2–4 weeks
(‘enzyme-replacement therapy’) or oral administration of
medicine that reduces the amount of glucosylceramide
substrate produced (‘substrate reduction’), thereby all-
owing any available enzyme to function more efficiently.
Fortunately, not all patients with GD require disease-
modifying treatment and the optimum timing of treatment
to prevent irreversible disease progression is unknown.
However, delaying treatment can lead to worse outcomes,
poorer prognoses18,19 and the development of preventable
late-onset complications.11 Untreated patients with GD
may have reduced quality of life relative to population
norms,20 and the clinical benefits of enzyme-replacement
and substrate reduction therapies in treatment-naïve
patients with GD are well established.21–29
The diagnostic guidance in Table 4 is deliberately lim-
ited to major factors, but our wider findings could inform
Table 2 Presenting clinical signs and co-variables in early type 3 GD
Round 2 Round 3














Major Splenomegaly 4.42 5 100 4.79 5 100
Disturbed oculomotor function (slow horizontal
saccades with unimpaired vision)
4.58 5 100 4.74 5 100
Thrombocytopenia 4.21 5 95 4.32 4 95
Myoclonus epilepsy 3.95 4 95 4.00 4 79
Anaemia 3.58 4 89 3.84 4 79
Hepatomegaly 3.74 4 95 3.79 4 79
Bone pain, including fractures 3.63 4 95 3.68 4 74
Disturbed motor function (impairment of primary motor
development)
3.11 3 79 3.68 4 79
Kyphosis 3.79 4 84 3.58 4 68
Minor Cardiac calcification 3.32 3 79 3.63 4 53
Growth retardation including low body weight 3.47 3 95 3.58 4 53
Pulmonary infiltrates 3.32 4 79 3.53 4 53
Cognitive deficit 3.21 3 84 3.53 4 53
Elevated ferritin levels 3.26 3 74 — — —
Bleeding, bruising or coagulopathy 3.26 3 74 — — —
Gammopathy – monoclonal or polyclonal 2.63 3 58 — — —
Elevated serum angiotensin-converting enzyme levels 3.11 3 63 — — —
Fatigue 2.79 3 63 — — —
Co-variables
Major Family history of GD 3.89 84 4.21 4 79
Minor Age ≤18 years 3.42 79 3.84 4 63
Blood relative who died of foetal hydrops and/or with
diagnosis of neonatal sepsis of uncertain aetiology
3.47 84 3.26 3 42
Family history of PD 2.79 63 — — —
Ashkenazi Jewish ancestry 2.47 37 — — —
Signs and co-variables that did not meet the threshold for importance (a score of ≥3 by >75% of respondents) were classified as minor and not taken
forward to round 3 for agreement rating. Signs and co-variables that met the threshold for agreement in round 3 (a score of ≥4 by >67% of respon-
dents) were classified as major; any that did not meet this threshold were classified as minor. †The Likert scale used for importance rating in round
2 was: 1 = not important; 2 = slightly important; 3 = important; 4 = very important; 5 = extremely important. ‡The Likert scale used for agreement
rating in round 3 was: 1 = strongly disagree; 2 = disagree; 3 = neither agree nor disagree; 4 = agree; 5 = strongly agree. §Percentage of respondents
(n = 19) is the proportion awarding a Likert scale score that met the selection criteria in each round. GD, Gaucher disease; PD, Parkinson disease.
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Figure 4 Major signs in Gaucher disease with continuous variables. Panel members were asked to indicate the levels of anaemia, hepatomegaly,
splenomegaly and thrombocytopenia that were considered consistent with, or unlikely to indicate, early type 1 Gaucher disease (GD) (n = 22) or early
type 3 GD (n = 19), and the levels of hyperferritinaemia consistent with, or unlikely to indicate, type 1 GD. Value ranges were proposed by the chairs
and categorised as mild, moderate or severe; panel members could also nominate a different range. ( ), Consistent; ( ), unlikely.
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development of an algorithm that is highly selective for
patients who may benefit from diagnostic GD testing. A
point-scoring system, such as that proposed in Table 5,
could be developed in which weighted scores are
assigned to each of the major signs and co-variables,
based on logistic regression analysis of retrospective data
from patients already diagnosed with GD. Similar tools
have been developed, validated prospectively and
Table 3 Hypotheses on barriers to early diagnosis of patients with GD in clinical practice and on the impact that the GED-C initiative could have on
clinical practice as judged by an international panel of experts – GED-C initiative Delphi rounds 2 and 3





















Owing to its rarity, there is a lack of awareness of GD
among healthcare professionals
4.14 4 95 4.41 5 86
Some early signs do not seem specific to GD, and their
clinical presentation can be variable or heterogeneous
3.91 4 100 4.27 4 91
Early signs are under-recognised as characteristic of
possible GD
4.23 4 100 4.23 4 91
GD is not normally considered as a differential diagnosis 4.09 4 100 4.18 4 86
Early signs can be mild and may be overlooked 4.18 4 100 4.18 5 77
Access to diagnostic tests is poor in some countries and
in some socioeconomic situations
3.82 4 91 4.14 5 77
Importance criteria
not met
Use of enzymatic diagnostic tests may be limited by cost
or logistical barriers or by an HCP’s unwillingness to
request them
3.18 3 64 — — —
Lack of a diagnostic algorithm 2.82 3 68 — — —
Geographic dispersion or socioeconomic division of
families can reduce awareness of a family history of GD





Patients could be diagnosed earlier in the disease
course, and monitored and managed appropriately to
improve long-term outcomes and quality of life
4.18 4 95 4.55 5 100
Earlier diagnosis would help to reduce serious or
irreversible late-onset complications, and comorbidities
of the disease could be avoided or managed
appropriately
4.41 5 100 4.55 5 95
Healthcare professionals’ awareness of the disease
might improve, and its inclusion as a differential
diagnosis might avoid unnecessary invasive diagnostic
procedures
4.00 4 95 4.41 4 95
With earlier diagnosis, patients could be followed up
from an earlier stage of disease, leading to a better
understanding of disease phenotypes and progression
3.86 4 86 4.36 5 86
Earlier diagnosis would allow family planning and genetic
counselling to be offered earlier
3.68 4 91 4.32 4 91
More rapid diagnosis would facilitate earlier
decision-making to support patients
4.05 4 100 4.14 4 82
It might lead to wider use and availability of diagnostic
testing
3.73 4 86 3.86 4 68
Consensus not
achieved
Goals for diagnosis would be clearer 3.50 4 82 3.50 4 55
Statements that did not meet the threshold for importance (a score of ≥3 by >75% of respondents) were not taken forward to round 3 for agreement
rating. Consensus was reached if statements met the threshold for agreement in round 3 (a score of ≥4 by >67% of respondents). †The Likert scale
used for importance rating in round 2 was: 1 = not important; 2 = slightly important; 3 = important; 4 = very important; 5 = extremely important.
‡The Likert scale used for agreement rating in round 3 was: 1 = strongly disagree; 2 = disagree; 3 = neither agree nor disagree; 4 = agree; 5 =
strongly agree. §Percentage of respondents (n = 22) is the proportion awarding a Likert scale score that met the selection criteria in each round. GD,
Gaucher disease; GED-C, Gaucher Earlier Diagnosis Consensus; HCP, healthcare professional.
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applied successfully in other disease areas.30 The arbi-
trary weighting values shown in Table 5 serve to illus-
trate the approach. Such an algorithm would expedite
the appropriate use of diagnostic testing early in the dis-
ease course.
The signs identified during this initiative were consis-
tent with those reported in the published literature.
There was 100% consensus that splenomegaly was a
major sign of both type 1 and type 3 GD, and spleno-
megaly was the single most-often-reported GD sign
among abstracts identified in our literature search
(Appendix S9). Among these was a longitudinal analysis
of data from a large number of children and adolescents
diagnosed with type 1 GD and registered in the Interna-
tional Collaborative Gaucher Group (ICGG) Gaucher
Registry, which showed that splenomegaly was the most
common presenting sign, reported in 95% of patients.31
Similarly, the five next most common presenting signs
reported in our literature search aligned with those iden-
tified by the GED-C expert panel, namely neurological
abnormalities, bone abnormalities (including pain, frac-
ture, crises and avascular necrosis), hepatomegaly,
thrombocytopenia and anaemia. Thus, the available evi-
dence strongly suggests that our consensus on major
signs in early GD is robust, valid and representative of
what is observed in clinical practice. In the ICGG analy-
sis, the most common patient-reported bone symptom
was pain; skeletal abnormalities, such as fractures, and
avascular necrosis were rare.31 Such signs were grouped
as ‘bone issues’ in our survey because the presence of
more severe signs of bone disease is consistent with GD,
but ideally our consensus would identify patients before
such signs were apparent. Some signs, such as
gammopathy and hyperferritinaemia, were reported
rarely or not at all in our literature search.
The barriers to earlier diagnosis of GD identified are
also supported by the literature, one of the greatest chal-
lenges being a lack of awareness of GD among
healthcare professionals, owing to its relative rarity.9,32
Furthermore, the heterogeneous nature of GD (patients
who are asymptomatic or who have only mild signs, dis-
ease progression at different rates in different tissues, or
variation between disease phenotypes) also impedes its
inclusion in differential diagnosis.9,14 An international
survey of haematologists and oncologists (n = 406) found
that only 20% of those surveyed considered GD as a dif-
ferential diagnosis in patients presenting with typical GD
signs (e.g. bone pain, cytopenia, hepatomegaly and
splenomegaly); leukaemia, lymphoma and multiple
myeloma were considered the most likely diagnoses.11
Limitations
Delphi methodology is widely used for gathering and
processing data from experts to achieve convergence of
opinion on a specific real-world issue, often in the
absence of sufficient evidence to provide adequate
guidance.15–17 The technique has been used to generate
simple, robust, expert experience-based consensus in a
variety of disease settings to improve diagnosis.33–38 An
analysis of the relationship between the characteristics of
Delphi surveys and variability in the consensus obtained
found there was a little associated variation in consensus
indices if the number of questions was in the range 6–40
(the maximum number in our survey was 26 in round 1);
similarly, variability was modest if the number of respon-
dents was in the range 6–50 (22 respondents to our sur-
vey).16 Although the Delphi technique is designed to
minimise potential noise and data distortion often associ-
ated with conventional group interactions,15–17 it can have
drawbacks. Regression to the mean is almost inevitable in
a consensus exercise and could dilute insightful or
nuanced responses offered by only a minority of
















Slow horizontal saccades with unimpaired vision




Family history of GD
GD should be included in differential diagnosis if two or more of these
factors are present and unexplained, particularly if one factor is spleno-
megaly. The more signs and co-variables that are present, the greater
would be the suspicion of GD. †Typically this would be unexplained
spleen enlargement of at least threefold, but spleen enlargement of less
than threefold would not necessarily exclude GD. ‡Mild or moderate
deviation from normal is most commonly seen with these signs in GD,
but severe deviation would not exclude GD. §Bone pain is more com-
mon in early GD than are more severe bone issues such as avascular
necrosis or fractures, but the presence of the latter may indicate that
GD is already advanced. ¶Neurological signs generally only manifest in
type 3 disease but are often preceded by the systemic signs listed. GD,
Gaucher disease.
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participants. However, the technique eliminates individ-
ual bias, and a generalised approach is probably appropri-
ate when creating non-specialist guidance.
Conclusion
The GED-C initiative has identified key clinical signs and
co-variables that are potentially indicative of type 1 GD
and of type 3 GD in its early stages. Clinicians who are
not specialists in GD can use this guidance to determine
whether GD needs to be considered in the differential
diagnosis of a patient and, when it is a possibility,
arrange lysosomal glucocerebrosidase testing and special-
ist involvement as soon as possible. Facilitating early
diagnosis of GD may ultimately lead to improved patient
quality of life and outcomes.
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Table 5 Prototype point-scoring system as a screen for diagnostic testing in Gaucher disease
Weighting Clinical sign or co-variable
Major signs and co-variables 3 points Splenomegaly (≥3× normal)
Disturbed oculomotor function (slow horizontal saccades with unimpaired vision)
2 points Thrombocytopenia, mild or moderate (platelet count, 50–150 × 109/L)
Bone issues, including pain, crises, avascular necrosis and fractures
Family history of Gaucher disease
Anaemia, mild or moderate (haemoglobin, 95–140 g/L)
Hyperferritinaemia, mild or moderate (serum ferritin, 300–1000 μg/L)
Jewish ancestry
Disturbed motor function (impairment of primary motor development)
Hepatomegaly, mild or moderate (≤3× normal)
Myoclonus epilepsy
Kyphosis
Gammopathy – monoclonal or polyclonal
1 point Anaemia, severe (haemoglobin, <9.5 g/dL)
Hyperferritinaemia, severe (serum ferritin, >1000 μg/L)
Hepatomegaly, severe (>3× normal)
Thrombocytopenia, severe (platelet count, <50 × 109/L)
Minor signs and co-variables 0.5 points Gallstones
Bleeding, bruising or coagulopathy
Leukopenia
Cognitive deficit
Low bone mineral density








Family history of Parkinson disease
Blood relative who died of foetal hydrops and/or with diagnosis of neonatal sepsis of uncertain
aetiology
The weighting scores shown are arbitrary and will need to be validated. Major clinical signs and co-variables were provisionally awarded a score of
2 points, and minor signs and co-variables a score of 0.5 points. Given that 100% consensus was reached for the signs splenomegaly and disturbed
oculomotor function (slow horizontal saccades with unimpaired vision) they were assigned a score of 3 points. Severe levels of the anaemia, hepato-
megaly, hyperferritinaemia and thrombocytopenia were deemed more likely to indicate other pathologies than Gaucher disease but did not exclude it,
so these were awarded a score of 1 point. Subject to validation in patient data, the scoring system will be used in the form of an online calculator to
generate a total score based on a patient’s presenting signs. The value of this total score will dictate whether diagnostic testing is recommended.
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